| __timestamp | Amneal Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 2983000000 |
| Thursday, January 1, 2015 | 109679000 | 3426000000 |
| Friday, January 1, 2016 | 118757000 | 3398000000 |
| Sunday, January 1, 2017 | 109046000 | 3878000000 |
| Monday, January 1, 2018 | 230435000 | 4056000000 |
| Tuesday, January 1, 2019 | 289598000 | 4381000000 |
| Wednesday, January 1, 2020 | 326727000 | 5151000000 |
| Friday, January 1, 2021 | 365504000 | 5246000000 |
| Saturday, January 1, 2022 | 399700000 | 5673000000 |
| Sunday, January 1, 2023 | 429675000 | 6090000000 |
| Monday, January 1, 2024 | 6091000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding spending patterns is crucial. Over the past decade, Gilead Sciences, Inc. and Amneal Pharmaceuticals, Inc. have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead's SG&A expenses surged by over 100%, peaking at approximately $6.1 billion in 2023. This reflects their aggressive market expansion and strategic investments. In contrast, Amneal's SG&A expenses grew by nearly 400%, reaching around $430 million in 2023, indicating a robust scaling strategy. While Gilead's spending dwarfs Amneal's, the latter's rapid growth rate highlights its dynamic approach in a competitive market. These trends underscore the diverse strategies employed by pharmaceutical companies to maintain and enhance their market positions.
Breaking Down SG&A Expenses: Sanofi vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.